Andreessen Marc L's Form 4 filing
Nautilus Biotechnology, Inc. (NAUT) · filed Jun 4, 2026
- Accession no.
- 0001231919-26-000599
- Filed
- Jun 4, 2026, 4:53 PM ET
- Trade date
- Jun 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $11.8M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Andreessen Marc LCIK 0001160077 | 10% Owner |
| Horowitz Benjamin ACIK 0001166586 | 10% Owner |
| AH Bio Fund II, L.P.CIK 0001725721 | 10% Owner |
| AH Equity Partners Bio II, L.L.C.CIK 0001725722 | 10% Owner |
| Andreessen Horowitz LSV Fund II, L.P.CIK 0001829357 | 10% Owner |
| AH Equity Partners LSV II, L.L.C.CIK 0001829384 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Common Stock | SSaleDisposed | −4,615,974 | $2.35 | −$10,847,538.9 | 11,682,032 | Indirect | |
| Jun 2, 2026 | Common Stock | SSaleDisposed | −384,026 | $2.35 | −$902,461.1 | 971,885 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.